We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Artificial Intelligence Platform Helps Find Combination Drug Treatments for COVID-19

By HospiMedica International staff writers
Posted on 08 Apr 2020
Healx (Cambridge, UK), an AI-powered biotech company specializing in rare diseases, is using its AI platform to develop drug combinations from approved drugs to contribute towards global efforts to find treatments for COVID-19. More...
This focus on combination therapies, where two or more drugs simultaneously target different aspects of the disease pathology, has the potential to ensure a more effective treatment.

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Many patients in this demographic suffer from pre-existing conditions relating to the heart and respiratory system which have been associated with the highest mortality rates amongst COVID-19 patients. Given this increased vulnerability to COVID-19, and the acute need for treatments, Healx is dedicating its time, knowledge, experience and technology towards fighting the viral infection. The treatments Healx intends to develop are also likely to have wide use amongst other patients identified as vulnerable.

Healx’s AI platform, Healnet, integrates and analyzes biomedical data from multiple sources to predict those combination therapies that are most likely to succeed in the clinic. The company’s AI drug discovery platform leverages public and proprietary biomedical data and features the world’s leading knowledge graph for rare diseases. Healnet is widely regarded as the world’s most efficient and comprehensive AI platform for rare diseases. Combination therapy candidates will be available in May for preclinical testing.

“The recent spread of COVID-19 is risking the lives of millions of rare disease patients across the world. The company’s AI technology is perfectly positioned to support the efforts to find treatments for COVID-19. Healx’s data-driven AI platform is able to predict, within weeks, which known drugs can be repurposed to treat other conditions such as COVID-19,” said Dr. David Brown, Healx Chairman and Co-founder. “This approach significantly shortens discovery-to-clinic timelines. Our AI is able to combine 2-3 existing drugs to formulate the most effective treatment. This approach ensures that any potential treatments we identify can be used by clinicians to help patients very quickly.”

Related Links:
Healx


Gold Member
12-Channel ECG
CM1200B
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Multi-Chamber Washer-Disinfector
WD 390
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Visual Abstract (Andrea Farolfi et al., Journal of Nuclear Medicine, 2026. DOI: 10.2967/jnumed.126.272108)

PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer After Nondiagnostic MRI

Prostate cancer can be difficult to detect when magnetic resonance imaging (MRI) findings are negative or inconclusive. Men with persistent clinical risk factors may still require biopsy, yet standard... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: WHX returns to Dubai Exhibition Centre, Expo City, and Dubai World Trade Centre from 5–28 January 2027 (Photo courtesy of World Health Expo)

World Health Expo to Showcase Trillion-Dollar Growth Across Pharma, Biotech, Longevity and Wellness at 2027 Edition

World Health Expo (WHX) expands with the new Pharma, Biotech, Longevity and Wellness industry sectors More than 235,000 professional visits, over 4,200 exhibitors and representatives from over... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.